Description

LGD 4033 is a novel nonsteroidal oral selective androgen receptor modulator being investigated as a potential treatment for muscle dystrophy and osteoporosis. Recent studies showed that LGD 4033 had a positive effect on muscle tissue in ovariectomized rats. The LGD treatment resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.

LGD-4033
CAS Number	1165910-22-4
Molar Mass	338.253 g·mol−1
Chemical Formula	C14H12F6N2O
IUPAC Name	4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile

Ostarine
CAS Number	1202044-20-9
Molar Mass	389.33g/mol-1
Chemical Formula	C19H10D4F3N3O3
IUPAC Name	3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide